These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29683442)

  • 1. Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy.
    Allan KJ; Mahoney DJ; Baird SD; Lefebvre CA; Stojdl DF
    J Vis Exp; 2018 Apr; (134):. PubMed ID: 29683442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. United virus: the oncolytic tag-team against cancer!
    Le Boeuf F; Bell JC
    Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
    Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
    Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic cancer therapy with a vaccinia virus strain.
    Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B; Hu Z
    Oncol Rep; 2019 Jan; 41(1):686-692. PubMed ID: 30365140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.
    Sampath P; Li J; Hou W; Chen H; Bartlett DL; Thorne SH
    Mol Ther; 2013 Mar; 21(3):620-8. PubMed ID: 23229093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo infection of live tissue with oncolytic viruses.
    Diallo JS; Roy D; Abdelbary H; De Silva N; Bell JC
    J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction between oncolytic viruses augments tumor killing.
    Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC
    Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic-adenovirus-expressed RNA interference for cancer therapy.
    Pei DS; Di JH; Chen FF; Zheng JN
    Expert Opin Biol Ther; 2010 Sep; 10(9):1331-41. PubMed ID: 20684738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A call to arms: using RNAi screening to improve oncolytic viral therapy.
    Mahoney DJ; Stojdl DF
    Cytokine Growth Factor Rev; 2010; 21(2-3):161-7. PubMed ID: 20207578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation oncolytic vaccinia vectors.
    Thorne SH
    Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
    Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.
    Bastin D; Aitken AS; Pelin A; Pikor LA; Crupi MJF; Huh MS; Bourgeois-Daigneault MC; Bell JC; Ilkow CS
    J Immunother Cancer; 2018 Jun; 6(1):62. PubMed ID: 29921327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
    Breitbach CJ; Thorne SH; Bell JC; Kirn DH
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Genome-Wide CRISPR-Cas9 Loss-of-Function Screening to Identify Host Restriction Factors Modulating Oncolytic Virotherapy.
    Muscolini M; Hiscott J; Tassone E
    Methods Mol Biol; 2023; 2589():379-399. PubMed ID: 36255638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death.
    Mahoney DJ; Lefebvre C; Allan K; Brun J; Sanaei CA; Baird S; Pearce N; Grönberg S; Wilson B; Prakesh M; Aman A; Isaac M; Mamai A; Uehling D; Al-Awar R; Falls T; Alain T; Stojdl DF
    Cancer Cell; 2011 Oct; 20(4):443-56. PubMed ID: 22014571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-oncogenic cell signaling machinery as a target for oncolytic viruses.
    Borrego-Diaz E; Mathew R; Hawkinson D; Esfandyari T; Liu Z; Lee PW; Farassati F
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1742-9. PubMed ID: 21740363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication.
    Edge RE; Falls TJ; Brown CW; Lichty BD; Atkins H; Bell JC
    Mol Ther; 2008 Aug; 16(8):1437-43. PubMed ID: 18560417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.